Allogenic human umbilical cord derived mesenchymal stem cell (Tuohua Biotechnology)

人脐带间充质干细胞（拓华生物）

Report date: 2026/04/15 20:02:38

Base Information

Drug NameAllogenic human umbilical cord derived mesenchymal stem cell (Tuohua Biotechnology)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapyCell and gene therapy > Cell therapy > Source of cells > Umbilical cord-derived
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsDiabetic NephropathiesRespiratory Distress Syndrome, AdultLung Diseases, Interstitial +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSuzhou Tuohua Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesJilin Tuohua Biological Technology Co LtdChangchun Tuohua Pharmaceutical Co LtdBeijing Tuohua Weiye Biotechnology Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsDiabetic NephropathiesRespiratory Distress Syndrome, AdultLung Diseases, Interstitial +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A